afternoon everyone can website results and for Good with of today, you. Thank thanks our press a on Therapeutics X:XX Eastern release quarter the we after section issued the results for Releases. first XXXX found Shortly under financial which Press call. these PM Time be Fate us joining Investors
and 'XX Form under our quarter for be was Investors filed the XX-Q thereafter Financial website XX, addition, In ended section shortly the can our on found March of Information.
XX, are obligation events statements the Except to and facts circumstances. future as circumstances with XX-Q should to or they Litigation the the the reflect I forward-looking of earnings see forward-looking disclaims to These in on that Form of included cause well Harbor of ended made forward-looking results involve placed questions to by as by uncertainties Private the in close and required forward-looking Before on materially change. the information, would the for issued XXXX. statements law, statement be we these provisions XXXX for not statements speak the filed statements. March the and update except management actual everyone risks date the this which statements as company's risk may was such conference begin, that of SEC as Fate from of facts, press made on Safe underlying only our today. the those quarter like under release can reliance Securities differ market after remind the as today factors call Therapeutics Please to that Reform these are Undue responses historical Act statements statements statements forward-looking any forward-looking disclaimer
the and Dr. our of Dr. Development Chief Valamehr, our our Officer; Financial Wayne Research Joining call Chief progress Chief Bob will the programs we for the that off-the-shelf, we the me key XXXX NK striving Chu, highlight Medical note disease few and made as franchises. and across several with Officer; four on iPSC-derived milestones several clinical are our first months next during Officer. our over achieve months treatment today's Today, to Ed cancer as Dulac, have well we of T are cell
cohort multi-cycle collaborations weekly begin achieve featured to addition, to Research Society NK am cells. XXXX with our to to cohort, favorable with with combination program at with and to the touch will billion our doses lymphoma, American and ongoing T single-dose have B-cell once dose. on multi-cycle I that rituximab, with highlight our escalated multi-dose, in we April enroll relapsed/refractory like under we have patients Association disease-specific our patients continued rituximab, X plan we Janssen in of X.X observed to to and malignancies we in in will May. in highlighting disease finally, programs treatment leadership on of and Ono today in cohorts advancing FTXXX at With programs multiple potential we setting off-the-shelf, momentum the our recent Therapy the I the In continue three data FTXXX cell hematologic expansion program and XXX strong combination FTXXX respect have American single-dose continue pleased million by a we in Cancer profile progress based respect we to preclinical schedule In upcoming With tumors. solid in per during this would are unveil milestones Gene announce at these now safety for FTXXX the And we and innovation for Cell we discuss and our that the our we studies. currently that and assess that continue to to cells dose advance Phase with multi-cycle as of the collaborations. and certain iPSC-derived
continue on In multi-cycle dose cohort per and dose addition, dose escalate million to this to and a per XXX enroll one with FTXXX dose. cells days at X.X to cells dose intend two we cohort multi-cycle XX two administered billion
from clonal receptor for expression. disruption novel are CAR In biolelic constant line FTXXX created CDXX-targeted from for line addition, undergo promoting the clonal XXX we alpha investigation. T locus, iPSC T master integrated a cell receptor enthusiasm ever a first program, single ensuring a and has cell therapy expression is that of clinical seeing cell investigator complete our iPSC manufactured construct, FTXXX into The CAR to the uniform T iPSC
we We to escalated now announce cohort dose XX that to the are pleased cells million from million XXX have single-dose cells.
cells the are to no We greater events. at with continuing cleared which backfill cohort XX or and single-dose no adverse FTXXX-related million Grade X toxicities dose-limiting
we XX administered cohort, single-dose a FTXXX per dose. been and the multi-dose multi-dose have cells at days three million to patients with cohort on first one, And in this the cohort five. also enrolling addition are treated In
As we cell to lines we for therapy, CAR CDXX-targeted on unmet pathways exists progressed continue patients especially who registrational a consider therapy. of critical need T multiple lymphoma, in believe have relapsed/refractory B-cell
patients refractory about CAR study the in it are RMAT progressed therapy. with T autologous our engage hold XX% design led discuss prior improvements FTXXX is weeks FDA patients cell that for coming following experience who While the or Under to and progression. a will CDXX-targeted and in have CAR CAR patients cell important FDA-approved to CDXX-targeted proposed patients, to remember outcomes treatment majority remarkable to has primary plan therapy the multi-disciplinary meeting relapsed to responding of ultimately of T disease in we designation, our pivotal therapy relapsed/refractory T cell
Under designation, we X% RMAT And survival and Annual rates Hematology from Importantly, product ranging of also presented five data seven overall months. XXXX discuss to American FTXXX of treatment CMC are recent no topics plan key the our first-of-kind poor to for the FDA platform. to outcomes therapies with response complete patients. retrospective XX% with demonstrates our to the iPSC of standard from Society administered applicable analysis these therapies at ranging available Meeting real-world of extremely
With to facility and believe the scheduled submission BLA initial of launch. second CMC with necessary expertise we equipped commercial fulfill capabilities manufacturing for the trial mid-XXXX, in-house are we launch conduct, requirements operational GMP our pivotal well that for are and
aggressive pathway We continue to whether end cell are CAR critical to and development that believe launch CDXX-targeted on represents of FTXXX setting autologous be working FTXXX with the previously the treated with for XXXX a need a T pivotal fast-to-market that or we with the T cell by post-CAR potential unmet based lymphomas therapy. study, patients
R-CHOP. lymphomas the that with standard In in with to into delivery of setting, lymphomas. to lymphoma, plus cycles as XXXX, with to the leaders regimens in we FTXXX aggressive at we of clinical allowance with of the many the setting potential investigators to for on cancer. with benefit relapsed/refractory delivering an to XXX end, that of patients schema to are off-the-shelf without FTXXX with FTXXX transform cleared community Cy/Flu chemotherapy FTXXX the ongoing the first-line from continue our now frontline the To with doses with multiple With heavily of cell cell-based In expect as disease and outcomes once the we conditioning begin XXXX, aggressive protocol to in opinion relapsed/refractory proposed the doses addition submit to The to cells myeloma, of administering therapies million cells stage patients includes of its escalation at subject schedule FTXXX program months, transformative X R-CHOP conditioning the in patients administered dose-limiting six by chemotherapy is an million seeking respect treatment FTXXX and treatment we community per R-CHOP, add-on six FTXXX patients each protocol setting outcomes enrollment a pretreated in over plan past also has believe without reach FTXXX patients FDA. who key combination and might with no dose up studies. half newly toxicities setting weekly XXX per daratumumab, In the dose. the to with standard of with three community earlier dose immunochemotherapy our cancer Phase patients Cy/FLu IND of have immunotherapy. treatment the enroll to second to quarter second B-cell multi-dose for in We one treating brings and dose, worked immunochemotherapy the the diagnosed to patients several of add-on
XXX million the and In program, [Technical at first XXX patients monotherapy the addition, cells combination toxicities no single-dose respect FTXXX single-dose we in to with cohort the dose-limiting in now at treated have daratumumab million cohort with as Difficulty] cleared with cells. our
preparing per monotherapy cohorts administered the with and at of doses X is in patients days currently as in designed billion and company's are FTXXX AML, FTXXX patients relapsed/refractory once-weekly on study dose. enrolling FTXXX one of of is multi-dose three initiate We In as which escalation daratumumab. to combination assess Phase XX to the monotherapy setting with X cells
well Phase FTXXX targets on multi-center the I'm a proteins with clinical the as domains or reported positive therapeutic single the the High stress, improved non-cleavable uniquely MICA MICA for from solid to targeting a proteins daratumumab histocompatibility been assess which tumor iPSC of of iPSC-derived studies of novel designed with is which by MICB proteolytic antibody-dependent company's the an patients alpha-X The CAR complex of solid was alpha-X potential potential X bank of FTXXX program high-affinity, tenants X to to addition, the receptor company's In master In tumors, CDXX-targeted and expression FTXXX, initiate first and mediated loss cytotoxicity product is X these elements, domain the incorporates created iPSC-engineered the billion of the pleased patients per dose is expression proteins and the induced a at for in maximize investigator-initiated recognized mechanism. cells as overcome tumors. solid for to antibody shedding tumors, of leukemic common FTXXX trial study is Both and We that mechanisms significantly poised CAR clonal announce are and can functional by four enrolling of transformation, many mechanisms Fc proteolytic is MICB and CDXX drive Class major which tumors. MHC escalation. to NK X-related combination also solid of cellular further targeting shedding. include we therapy has the blasts escape with novel MICA for damage of tumor dose. although cell including designed the antibody cellular monoclonal outcomes CAR believe escape with ability MICB. a as to monoclonal CDXX attack synergize setting alpha-X Class
release final schedule we clinical are sites of first conducting to are and six clinical and of end forward monoclonal iPSC-derived designed multiplexed-engineered manufacture treatment completed testing FTXXX of candidates FTXXX first as updates multi-dose, NK clinical our successfully in advanced the of to study's the half is T have product antibody therapy patient We franchises solid our initiate May. working arm with multi-cycle assess with for a and by enrollment XXXX. in study to disease tumors. second and cell providing We The across for look monotherapy the combination
Turning to collaborations Ono. Janssen with and our
strong cell treatment are in our NK to solid cell we to have submit Janssen, candidates. and product collaboration We for with CAR with we T iPS-derived initiated CAR of malignancies IND momentum show candidates. collaboration Under and activities for these bringing the hematologic now patients both iPS-derived and continue working applications Janssen to And IND-enabling two prepare multiplexed-engineered actively CAR tumors. for together NK of candidates
an We each of share subject in prior each profits alongside Janssen these to For submission and of maintains its initiate collaboration maintain co-commercialize payment the in option to losses the the and option clinical to of development. collaboration to candidate. right IND candidates, worldwide Janssen U.S. equally fee
successfully contribute contributed has As binding of our collaboration has targeting Ono designate for antigens. and the novel now And under cell novel preclinical generation a Ono, multiplexed-engineered CAR we solid novel to Janssen antigens. now with master T has have targeting three domain solid four antigen. a domains have the to antigens. the candidates tumor-associated targeting reminder, and targeting we collaboration domains a iPS-derived Under collaboration, the cell for collaboration binding up achieved right binding our Janssen milestones now designated tumor-associated a and tumor-associated candidate targeting bank three antigen all contributed initiated
clinical payment are to solid initiate its Ono development candidate collaboration and worldwide cell and at exercise IND-enabling collaboration CAR in CAR to activities rights tumor third commercialization, right quarter option the We U.S. its Ono. the subject and the option, during co-develop T candidate cell while fee, to to Europe poised for has the of for alongside an T of the we which maintain the XXXX, time, co-commercialize
and pleased success poised to very cell the and developing with tumors. solid now Janssen CAR achieved we product of have are liquid milestones are connection the Ono and by iPS-derived We CAR and with And the candidates in significant course for NK with in multiplexed-engineered next T over Janssen three exercised achieve to Ono months. option both six we
Turning to our leadership and innovation. continued
receptor for patient continue and for the of that Research in off-the-shelf critical designed NK vitro eliminate development presence lymphoconditioning, ADR-armed on persist NK defense and we invest therapy or immunotherapy. requirement in solid which patient and allo-reactive allo-reactive host of activity proof conditioning deplete cell multiplexed-engineered durable allo-reactive cells patient for escape building tumor need in presence functional barriers in antigen system. in to the iPS-derived persistence cells cell our host T potential cancer and of that upregulated and X-XBB We ADR-armed therapies the to data the new These alloimmune is limit first-in-class candidates conditioning of exhibit American microenvironment. show the undergo designed immune ADR pipeline Cancer incorporation we tumors, such tumor through At and a demonstrate that targets functional without T to to preclinical for to cells. a have antitumor to including synthetic requiring April, at activity antitumor the presented immune the potent the elements the induce provide product In chemotherapy Association concept as overcome enhanced in cells preclinical administering models, of vivo immunosuppressive cell-based
cancer In In CDXFR CAR our be off-the-shelf synergize engagers. addition, chimeric must disease. to we and combine with eliminated fusion therapies, prevent to bispecific immunotherapies which receptor developing is cell-based to showcased novel designed expression T or cell CDX enable graft-versus-host TCR off-the-shelf CDX
cells the our CDXFR CAR with expression engagement However, preclinical hnCDXX of vitro at NK and the synergize proof loss CAR of In cells month, enables with These heterogeneous NK this cytotoxicity CDXFR target-specific dual-antigen and TCR models, product American CDX of Similarly, have effectively surface the we Therapy, product with cells monoclonal armed a TCR a to engagers demonstrate iPSC antibody platform, including that bispecific plan T Society in CDXFR-armed, no and synergy that in most like of T leads showed combine expression CDX iPS-derived abstracts expression. solid we provide Fc date. sophisticated Cell and iPS-derived therapy, present our through enabled to of to engager, our tumors. to nine data iPS-derived on that proprietary CAR for enables absence lack bispecific expression. surface our Later multi-pronged attack multiplexed-engineered CDX cell unveiling & preclinical much combination concept targeting. Gene receptor covering naturally
synthetic developing targeting modalities, product modes for tumors are a a promote functional to receptor including homing redirector cell as tumor three well signaling to in off-the-shelf an novel to beta as repressive We heterogeneity candidate synthetic of traffic That CXCRX solid TGF to tumors. in promote incorporates solid and T tumor seven the into currently microenvironment. iPS-derived overcome activation tumor receptor response CAR novel
to tissue. preclinical target, that recognition data ability antigen novel normal the not selectivity antigen yet first cells to on solid like domain I our tumor the between the exhibits quarter binding unique this cell We financial now would activities to tumor into candidate our to T year. disclose will will the IND-enabling product results. turn construct Ed look discriminate expressed forward tumors tumor we highlight first call with CAR While show advancing later versus iPS-derived off-the-shelf solid and over CAR to for
